Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

Bristol Myers Squibb raised its full-year revenue and profit forecast on Thursday after strong sales of blood thinner Eliquis and newer medicines such as heart drug Camzyos and anemia treatment Reblozyl helped second-quarter results top analysts' estimates.

Shares of the U.S. drugmaker rose as much as 2.5% in premarket trading.

The company reported second-quarter revenue of $12.97 billion, up 6% from a year earlier and above analysts' average estimate of $11.75 billion, according to LSEG data. Adjusted earnings were $2.04 per share, topping expectations of $1.59 per share.

The company raised its full-year revenue forecast to $49 billion to $50 billion from its previous range of $46 billion to $47.5 billion. Bristol Myers now sees adjusted 2026 earnings of $6.75 to $7.00 a share, up from its prior view of $6.05 to $6.35.